You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: May 11, 2024

Details for Patent: 10,821,074

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 10,821,074 protect, and when does it expire?

Patent 10,821,074 protects KYNMOBI and is included in one NDA.

This patent has one hundred and sixty-two patent family members in nineteen countries.

Summary for Patent: 10,821,074

Title:	Sublingual and buccal film compositions
Abstract:	The present invention relates to products and methods for treatment of various symptoms in a patient, including treatment of pain suffered by a patient. The invention more particularly relates to self-supporting dosage forms which provide an active agent while providing sufficient buccal adhesion of the dosage form. Further, the present invention provides a dosage form which is useful in reducing the likelihood of diversion abuse of the active agent.
Inventor(s):	Myers; Garry L. (Kingsport, TN), Hilbert; Samuel D. (Jonesboro, TN), Boone; Bill J. (Johnson City, TN), Bogue; B. Arlie (New Carlisle, IN), Sanghvi; Pradeep (Schererville, IN), Hariharan; Madhusudan (Munster, IN)
Assignee:	AQUESTIVE THERAPEUTICS, INC. (Warren, NJ)
Application Number:	16/048,243
Patent Claim Types: see list of patent claims	Composition; Formulation;

Drugs Protected by US Patent 10,821,074

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-001	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-002	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-003	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-004	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
Sumitomo Pharma Am	KYNMOBI	apomorphine hydrochloride	FILM;SUBLINGUAL	210875-005	May 21, 2020		DISCN	Yes	No	⤷ Try a Trial	⤷ Try a Trial	Y				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 10,821,074

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	077803	⤷ Try a Trial
Austria	E536868	⤷ Try a Trial
Austria	E536869	⤷ Try a Trial
Austria	E553746	⤷ Try a Trial
Australia	2002332118	⤷ Try a Trial
Australia	2002348432	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.